Larry Ellison, co-founder and executive chairman of Oracle Corp., speaks during the Oracle OpenWorld conference in San Francisco on Oct. 22, 2018.
David Paul Morris | Bloomberg | Getty Images
Oracle unveiled a brand-new electronic health record on Tuesday, its most significant health-care product update since acquiring the medical records giant Cerner for $28 billion in 2022.
An electronic health record, or an EHR, is a digital version of a patient’s medical history that’s updated by doctors and nurses over time. EHR software can be complex and cumbersome for clinicians to use, but it’s become an integral component of the modern U.S. health-care system.
Oracle’s latest EHR is equipped with cloud and artificial intelligence capabilities that will make it easier to navigate and set up, the company said. There are no menus or drop-down screens, and doctors can pull up the information they need by asking questions with their voices. Ideally, this will allow doctors to spend less time searching through records and more time caring for patients, Oracle said.
“It’s not just a scribe. It’s not an assistant. It’s almost like having your own resident,” Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences, told CNBC in an interview.
Oracle’s new offering could help boost its position within the fiercely competitive EHR market, where it has struggled to maintain its footing in recent years. In 2023, Oracle saw its largest net hospital loss on record while market leader Epic Systems, Oracle’s top rival, was the only company that saw a net increase in acute care market share, according to a report from KLAS Research.
Cerner contributed $5.9 billion to Oracle’s total revenue in fiscal 2023. Epic generated $4.9 billion in revenue last year.
Oracle co-founder and Chairman Larry Ellison delivers a keynote address during the Oracle OpenWorld on October 22, 2018 in San Francisco, California.
Justin Sullivan | Getty Images
The new EHR has been in the works since Oracle acquired Cerner, but it was not built on top of Cerner’s existing infrastructure, Verma said. That means current Cerner customers will have to decide whether to migrate to the separate system.
“Just think about crumbling infrastructure in a house, you’re not going to put new things on top of it,” she said. “That was the conclusion that we came to when we looked at the Cerner technology, so what we’re introducing to the market is something that’s brand new.”
Suhas Uliyar, Oracle’s senior vice president for product management in clinical and health-care AI, walked CNBC through a virtual demo of the new EHR. He showcased what it might look like for a doctor to get up to speed, respond to messages and fill prescriptions ahead of a day packed full of patient visits.
The EHR is browser based, and physicians will see a search bar and a chronological list of their appointments when they open it. The interface is very simple. A doctor can click on the microphone in the search bar and ask questions like, “How many openings do I have for today?” or “How many new patients do I have on schedule for today?” The doctor will then get an AI-generated answer within seconds.
If a doctor clicks on a patient, they’ll open their chart, where they can find AI summaries as well as more detailed explanations of their medical history. The physician can see what’s changed since the patient’s last visit, whether they’re taking any new medication and other details like lab results, clinical documentation, past treatments, risk factors, messages, allergies and vitals.
Additionally, the doctor can click the microphone and ask patient-specific questions like “Has she ever complained about panic attacks or shortness of breath?,” “Has he had a CT screening for lung cancer, and are his vaccinations up to date?” or “Which antibiotics have you treated her urinary tract infection with?”
“It’s going through the entire history, all the records, and it gives me a very specific answer,” Uliyar said. “I didn’t have to go scroll through 15 different documents and find that.”
The voice-activated questions can build on one another, and the EHR’s AI will start to learn the doctor’s habits, like the types of medications they prescribe and refill often. Even when Uliyar stumbled over his words or didn’t phrase a question exactly right, the system still pulled up the information he was looking for.
If a doctor wants to go into more detail or double-check an AI-generated answer within the new EHR, they can always click on the citation and look through the original record that’s referenced, Uliyar said. And answers that include content like medication dosage information or other evidence-based recommendations will link to validated databases, he added.
Traders work on the floor of the New York Stock Exchange (NYSE) on July 12, 2023 in New York City.
Spencer Platt | Getty Images
While Oracle has been developing its new EHR, the company has also been rolling out features to existing Cerner customers to try and improve their experience with the product. Uliyar said many of these features, including Oracle Health Clinical AI Agent (formerly called Oracle Clinical Digital Assistant), are already embedded within the new EHR.
Oracle announced the general availability of Clinical AI Agent in June, and it aims to automate much of the documentation that doctors are responsible for.
Physicians can access the Clinical AI Agent through an app on their phone, and they hit a button to record their visits with patients. Once they stop recording, Oracle’s AI automatically generates a clinical note based on the appointment, so the doctorsno longer need to write it themselves.
Around 70 customers are already using the Clinical AI Agent, Uliyar said. The company is currently building a similar tool for nurses.
Since the Clinical AI Agent is already embedded within the new EHR, customers will not have to worry about integrating it. The tool will also remain available as a stand-alone product that’s EHR agnostic, Uliyar said.
The early adopter program for Oracle’s new EHR begins next year, and Oracle said it will work with customers to determine the customizations they need. The company has been moving its health-care customers to the cloud, so that should make the EHR implementation process much easier, Verma said.
“We see it as very disruptive to the market,” she said. “Our EHR is going to solve a lot of long-standing problems that we’ve had in health care.”
Startup Figure AI is developing general-purpose humanoid robots.
Figure AI
Figure AI, an Nvidia-backed developer of humanoid robots, was sued by the startup’s former head of product safety who alleged that he was wrongfully terminated after warning top executives that the company’s robots “were powerful enough to fracture a human skull.”
Robert Gruendel, a principal robotic safety engineer, is the plaintiff in the suit filed Friday in a federal court in the Northern District of California. Gruendel’s attorneys describe their client as a whistleblower who was fired in September, days after lodging his “most direct and documented safety complaints.”
The suit lands two months after Figure was valued at $39 billion in a funding round led by Parkway Venture Capital. That’s a 15-fold increase in valuation from early 2024, when the company raised a round from investors including Jeff Bezos, Nvidia, and Microsoft.
In the complaint, Gruendel’s lawyers say the plaintiff warned Figure CEO Brett Adcock and Kyle Edelberg, chief engineer, about the robot’s lethal capabilities, and said one “had already carved a ¼-inch gash into a steel refrigerator door during a malfunction.”
The complaint also says Gruendel warned company leaders not to “downgrade” a “safety road map” that he had been asked to present to two prospective investors who ended up funding the company.
Gruendel worried that a “product safety plan which contributed to their decision to invest” had been “gutted” the same month Figure closed the investment round, a move that “could be interpreted as fraudulent,” the suit says.
The plaintiff’s concerns were “treated as obstacles, not obligations,” and the company cited a “vague ‘change in business direction’ as the pretext” for his termination, according to the suit.
Gruendel is seeking economic, compensatory and punitive damages and demanding a jury trial.
Figure didn’t immediately respond to a request for comment. Nor did attorneys for Gruendel.
The humanoid robot market remains nascent today, with companies like Tesla and Boston Dynamics pursuing futuristic offerings, alongside Figure, while China’s Unitree Robotics is preparing for an IPO. Morgan Stanley said in a report in May that adoption is “likely to accelerate in the 2030s” and could top $5 trillion by 2050.
Concerns about stock valuations in companies tied to artificial intelligence knocked the market around this week. Whether these worries will recede, as they did Friday, or flare up again will certainly be something to watch in the days and weeks ahead. We understand the concerns about valuations in the speculative aspects of the AI trade, such as nuclear stocks and neoclouds. Jim Cramer has repeatedly warned about them. But, in the past week, the broader AI cohort — including real companies that make money and are driving what many are calling the fourth industrial revolution — has been getting hit. We own many of them: Nvidia and Broadcom on the chip side, and GE Vernova and Eaton on the derivative trade of powering these energy-gobbling AI data centers. That’s not what should be happening based on their fundamentals. Outside of valuations, worries also center on capital expenditures and the depreciation that results from massive investments in AI infrastructure. On this point, investors face a choice. You can go with the bears who are glued to their spreadsheets and extrapolating the usable life of tech assets based on history, a seemingly understandable approach, and applying those depreciation rates to their financial models, arguing the chips should be near worthless after three years. Or, you can go with the commentary from management teams running the largest companies driving the AI trade, and what Jim has gleaned from talking with the smartest CEOs in the world. When it comes to the real players driving this AI investment cycle, like the ones we’re invested in, we don’t think valuations are all that high or unreasonable when you consider their growth rates and importance to the U.S., and by extension, the global economy. We’re talking about Nvidia CEO Jensen Huang, who would tell you that advancements in his company’s CUDA software have extended the life of GPU chip platforms to roughly five to six years. Don’t forget, CoreWeave recently re-contracted for H100s from Nvidia, which were released in late 2022. The bears with their spreadsheets would tell you those chips are worthless. However, we know that H100s have held most of their value. Or listen to Lisa Su, CEO of Advanced Micro Devices , who said last week that her customers are at the point now where “they can see the return on the other side” of these massive investments. For our part, we understand the spending concerns and the depreciation issues that will arise if these companies are indeed overstating the useful lives of these assets. However, those who have bet against the likes of Jensen Huang and Lisa Su, or Meta Platforms CEO Mark Zuckerberg, Microsoft CEO Satya Nadella, and others who have driven innovation in the tech world for over a decade, have been burned time and again. While the bears’ concerns aren’t invalid, long-term investors are better off taking their cues from technology experts. AI is real, and it will increasingly lead to productivity gains as adoption ramps up and the technology becomes ingrained in our everyday lives, just as the internet has. We have faith in the management teams of the AI stocks in which we are invested, and while faith is not an investment strategy, that faith is based on a historical track record of strong execution, the knowledge that offerings from these companies are best in class, and scrutiny of their underlying business fundamentals and financial profiles. Siding with these technology expert management teams, over the loud financial expert bears, has kept us on the right side of the trade for years, and we don’t see that changing in the future. (See here for a full list of the stocks in Jim Cramer’s Charitable Trust, including NVDA, AVGO, GEV, ETN, META, MSFT.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: The S & P 500 bounced back Friday, recovering from the prior session’s sharp losses. The broad-based index, which was still tracking for a nearly 1.5% weekly decline, started off the session a little shaky as Club stock Nvidia drifted lower after the open. It was looking like concerns about the artificial intelligence trade, which have been dogging the market, were going to dominate back-to-back sessions. But when New York Federal Reserve President John Williams suggested that central bankers could cut interest rates for a third time this year, the market jumped higher. Rate-sensitive stocks saw big gains Friday. Home Depot rose more than 3.5% on the day, mitigating a tough week following Tuesday’s lackluster quarterly release. Eli Lilly hit an all-time high, becoming the first drugmaker to reach a $1 trillion market cap. TJX also topped its all-time high after the off-price retailer behind T.J. Maxx, Marshalls, and HomeGoods, delivered strong quarterly results Wednesday. Carry trade: We’re also monitoring developments in Japan, which is dealing with its own inflation problem and questions about whether to resume interest rate hikes. That brings us to the popular Japanese yen carry trade, which is getting squeezed as borrowing costs there are rising. The yen carry trade involves borrowing yen at a low rate, then converting them into, say, dollars, and investing in higher-yielding foreign assets. That’s all well and good when the cost to borrow yen is low. It’s a different story now that borrowing costs in Japan are hitting 30-year highs. When rates rise, the profit margin on the carry trade gets crunched, or vanishes completely. As a result, investors need to get out, which means forced selling and price action that becomes divorced from fundamentals. It’s unclear if any of this is adding pressure to U.S. markets. We didn’t see anything in the recent quarterly earnings reports from U.S. companies to suggest corporate fundamentals are deteriorating in any meaningful way. That’s why we’re looking for other potential external factors, alongside the well-known concerns about artificial intelligence spending, the depreciation resulting from those capital expenditures, and general worries about consumer sentiment and inflation here in America. Wall Street call: HSBC downgraded Palo Alto Networks to a sell-equivalent rating from a hold following the company’s quarterly earnings report Wednesday. Analysts, who left their $157 price target unchanged, cited decelerating sales growth as the driver of the rerating, describing the quarter as “sufficient, not transformational.” Still, the Club name delivered a beat-and-raise quarter, which topped estimates across every key metric. None of this stopped Palo Alto shares from falling on the release. We chalked the post-earnings decline up to high expectations heading into the quarter, coupled with investor concerns over a new acquisition of cloud management and monitoring company Chronosphere. Palo Alto is still working to close its multi-billion-dollar acquisition of identity security company CyberArk , announced in July. HSBC now argues the stock’s risk-versus-reward is turning negative, with limited potential for upward estimate revisions for fiscal years 2026 and 2027. We disagree with HSBC’s call, given the momentum we’re seeing across Palo Alto’s businesses. The cybersecurity leader is dominating through its “platformization” strategy, which bundles its products and services. Plus, Palo Alto keeps adding net new platformizations each quarter, converting customers to use its security platform, and is on track to reach its fiscal 2030 target. We also like management’s playbook for acquiring businesses just before they see an industry inflection point. With Chronosphere, Palo Alto believes the entire observability industry needs to change due to the growing presence of AI. We’re reiterating our buy-equivalent 1 rating and $225 price target on the stock. Up next: There are no Club earnings reports next week. Outside of the portfolio, Symbotic, Zoom Communications , Semtech , and Fluence Energy will report after Monday’s close. Wall Street will also get a slew of delayed economic data during the shortened holiday trading week. U.S. retail sales and September’s consumer price index are scheduled for release early Tuesday. Durable goods orders and the Conference Board consumer sentiment are released on Wednesday morning. (See here for a full list of the stocks in Jim Cramer’s Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.